Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent’s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial, adoption, and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What are U.S. dermatologists’ awareness of and familiarity with Dupixent, and what are their perceptions of the product?
  • To which patients are prescribers of Dupixent prescribing the product, what are their reasons for prescribing it, and how satisfied are they with it?
  • What promotional messages and activities are Sanofi and Regeneron using to support Dupixent’s launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with other recent product launches for AD?

Methodology: ~75-100 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Dupixent

Key companies: Sanofi/Regeneron

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Dupixent Launch Tracking Wave 2 (US)
    • Key Findings
      • Benchmarking Dupixent Launch Success vs. the Competition
        • Key Findings
      • Prescriber and Nonprescriber Profiles
        • Differences Between Dupixent Prescribers and Nonprescribers
        • Differences Between Dupixent Prescriber and Nonprescriber Profiles
      • Dupixent Awareness and Perceptions
        • Unaided and Aided Awareness of Dupixent
          • Unaided Awareness of Recently Approved Drugs for Atopic Dermatitis
          • Awareness of Dupixent
          • Awareness of Dupixent's Approval for AD
          • Awareness of the Administration of Dupixent
          • Estimated Cost of Dupixent
        • Familiarity with Dupixent
          • Sources of Familiarity with Dupixent
            • Initial Reaction to and Interest in Dupixent
              • Initial Reaction to Dupixent After Viewing Product Profile
              • Level of Interest in Dupixent
            • Impressions of Dupixent
              • Existence of Dupixent Attributes About Which Dermatologists Were Unaware
              • Aspects of Dupixent Profile of Which Dermatologists Were Unaware
              • Perceived Uniqueness of Dupixent
              • Risk-Benefit Ratio of Dupixent
              • Perceived Value of Dupixent Attributes
              • Unaided Advantages of Dupixent
              • Unaided Disadvantages of Dupixent
            • Prescriber and Nonprescriber Profiles
              • Difference Between Dupixent Prescriber and Nonprescriber Profiles
          • Dupixent Trial and Use
            • Willingness to Prescribe Dupixent
              • Impact of Attributes on Willingness to Prescribe Dupixent
              • Mean Impact of Attributes on Willingness to Prescribe Dupixent
            • Number of Patients Currently Receiving Dupixent
              • Agents Currently Prescribed to AD Patients
              • Mean Dupixent Patient Volume
              • Dupixent Patient Volume
              • Timing of Dupixent Prescription
              • Mean Timing of Dupixent Prescription
              • Dupixent Discontinuation Rate
              • Mean Dupixent Discontinuation Rate
              • Timing of Dupixent Discontinuation
              • Reasons for Discontinuing Dupixent
              • Agents to Which Patients Switched After Discontinuing Dupixent
              • Dupixent Patients by Disease Severity
              • Origination of Patients Treated with Dupixent
              • Agents from Which Patients Were Switched to Dupixent
              • Reasons for Switching to Dupixent from Previous Therapy
              • Agents to Which Dupixent Was Added
              • Reasons for Prescribing Dupixent
              • Number of Patient Inquiries for Dupixent
              • Mean Number of Patient Inquiries for Dupixent
              • Result of Specific Patient Requests for Dupixent
            • Reasons for Not Yet Prescribing Dupixent
              • Anticipated Use of Dupixent
                • Nonprescriber Timeline for Dupixent Trial
                • Candidates for Dupixent by AD Patient Population
                • Candidates for Dupixent by Treatment History
                • Therapies That Dupixent Is Likely to Replace
                • Obstacles to Prescribing Dupixent
                • Percentage of Patients Expected to Receive Prescription Drug Treatment for AD in the Next Six Months: Mean
                • Percentage of Patients Expected to Receive Prescription Drug Treatment for AD in the Next Six Months
                • Agents That Dermatologists Expect to Prescribe to AD Patients in the Next Six Months
              • Dupixent Performance on Key Attributes
                • Overall Satisfaction with Dupixent
                • Ease of Dupixent's Managed Care Approval Process
                • Requirements for Dupixent's Managed Care Approval
                • Mean Total Dupixent Performance on Key Attributes
                • Dupixent Performance on Key Attributes: Prescribers vs. Nonprescribers
                • Mean Dupixent Performance on Key Attributes: Prescribers vs. Nonprescribers
                • Total Dupixent Performance on Key Attributes
                • Dupixent Performance on Key Attributes: Prescribers vs. Nonprescribers
            • Effectiveness of Face-to-Face Detailing for Dupixent
              • Frequency and Reach of Dupixent Sales Representatives
                • Most Recent Contact with a Dupixent Sales Representative
                • Mean Frequency of Dupixent Representatives' Visits to Surveyed Dermatologists
                • Frequency of Dupixent Representatives' Visits to Surveyed Dermatologists
                • Samples Provided by Dupixent Representatives
                • Surveyed Dermatologists' Interest in Samples from Dupixent Representatives
                • Surveyed Dermatologists' Use of Dupixent Samples
              • Satisfaction with Dupixent Sales Representative
                • Mean Rating of Dupixent Representatives' Sales Performance
                • Sales Performance of Dupixent Representatives
              • Dupixent Message Recall
                • Message Recall During Recent Detail
                • Ideal Dupixent Candidate Suggested by Representative
                • Materials Used During Dupixent Representatives' Visit
                • Agents Positioned Against Dupixent During Representative Visit
            • Appendix
              • Primary Market Research
                • Initial Reaction to Dupixent After Viewing Product Profile: Mean
                • Familiarity with Dupixent: Mean
                • Perceived Uniqueness of Dupixent: Mean
                • Perceived Value of Dupixent Attributes: Mean
                • Risk-Benefit Ratio of Dupixent: Mean
                • Mean Overall Satisfaction with Dupixent

          Author(s): Emily Schriner, M.P.H.

          Emily Schriner, M.P.H., is a business insights analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information. Ms. Schriner earned her master's degree in public health in nutrition at West Chester University of Pennsylvania. She completed an internship at Nemours Health Network in Wilmington, Delaware.